330
Participants
Start Date
January 31, 2012
Primary Completion Date
June 30, 2014
Study Completion Date
June 30, 2014
Lesinurad
Tablets, 400 mg once daily (QD)
Lesinurad
Tablets, 200 mg QD
Placebo
Tablets, Placebo QD
Febuxostat
80 mg
Grafton
Lausanne
Fribourg
Camperdown
Tauranga
Hamilton
Woodville South
Shenton Park
Hobart
New York
Mineola
Belle Vernon
Clairton
Pittsburgh
Scottdale
Duncansville
Sellersville
Jenkintown
Lansdale
Washington D.C.
Frederick
Richmond
Chesapeake
Suffolk
Virginia Beach
Danville
Morgantown
Winston-Salem
Durham
Greenville
Wilmington
Calabash
Columbia
Spartanburg
Mt. Pleasant
Greenville
Conyers
Johns Creek
Newnan
Savannah
Fleming Island
Port Orange
Vero Beach
Pembroke Pines
Pembroke Pines
Miami
Boynton Beach
Tampa
Tampa
Tampa
Winter Haven
Napels
East Brandenton
Brooksville
Birmingham
Memphis
Jackson
Olive Branch
Jackson
Lexington
Elizabethtown
Columbus
Middleburg
Wadsworth
Southfield
Kalamazoo
Fargo
Missoula
Gurnee
Chicago
Chicago
Springfield
Springfield
St Louis
Jefferson City
Little Rock
Little Rock
Oklahoma City
Oklahoma City
Dallas
Waco
Houston
Houston
Sugar Land
Victoria
San Antonio
Corpus Christi
Austin
Austin
Englewood
Denver
Denver
Meridian
Meridian
Pheonix
Peoria
Goodyear
Tucson
Los Angeles
Glendale
Rancho Cucamonga
La Jolla
San Diego
Irvine
Huntington Beach
Honolulu
Seattle
Trumball
Kelowna
Victoria
Halifax
London
Mississauga
Toronto
Québec
Kutno
Biatystok
Elblag
Gmina Końskie
Katowice
Krakow
Krakow
Poznan
Poznan
Lead Sponsor
Ardea Biosciences, Inc.
INDUSTRY